Drug Type Small molecule drug |
Synonyms Indigo Naturalis Extract |
Target |
Action agonists |
Mechanism AHR agonists(Aryl hydrocarbon receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H10N2O2 |
InChIKeyCRDNMYFJWFXOCH-UHFFFAOYSA-N |
CAS Registry479-41-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 2 | Taiwan Province | 01 Oct 2015 | |
Psoriasis vulgaris | Phase 2 | Taiwan Province | 01 Nov 2012 | |
Allergic asthma | Preclinical | Taiwan Province | 01 Dec 2024 | |
Retinal Dystrophies | Preclinical | China | 01 Jan 2024 | |
Retinal Dystrophies | Preclinical | China | 01 Jan 2024 |
Not Applicable | - | - | Indigo naturalis | ysuxpoussv(cqumlwbart) = IN induced invagination ynjewukglw (hhnjvocphk ) View more | - | 23 May 2021 | |
Phase 2 | 48 | Lindioil ointment | xklrrgtztt(kotfcrujyg) = xclsahrkro tdslfsutdu (odcxnbgsxm, 36.8% - 63.1%) | Positive | 25 Mar 2020 | ||
Vehicle ointment | xklrrgtztt(kotfcrujyg) = ddmgnxtneh tdslfsutdu (odcxnbgsxm, -8.2% - 47.4%) | ||||||
Phase 2/3 | 33 | tvvgzqydkn(jxjxzmzhft) = mvwunzkwnm snpuwvhsyq (nhtwagsaoc, 8.55) View more | - | 28 Aug 2019 |